$66.18
Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
Overview
52-week range
$30
$64
100% of range
Avg surprise (last 3)
+2.6%
Avg reaction (last 2)
-1.0%
50% positive
Latest IV / EM
62%
EM ±14.3% · $68 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-1.17 | $-1.17 | 0.0% | -41.0% | -4.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.15 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.07 | $-1.03 | -3.9% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.83 | $-0.94 | +11.7% | — | +2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.81 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.75 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.62 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.72 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$1.16 | -$1.07 | -8.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-112M | — | $-96M | $-94M | $-73M | — | $-74M | $-69M |
| Net income | $-102M | — | $-91M | $-85M | $-65M | — | $-63M | $-58M |
| EPS (diluted) | $-1.17 | — | $-1.15 | $-1.07 | $-0.83 | — | $-0.81 | $-0.75 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $546M | $199M | $105M | $135M | $117M | $143M | $88M | $137M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.11B | $561M | $480M | $500M | $566M | $635M | $660M | $728M |
| Total assets | $1.39B | $633M | $608M | $674M | $743M | $798M | $836M | $884M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $49M | $51M | $48M | $40M | $39M | $43M | $38M | $40M |
| Total equity | $1.34B | $582M | $560M | $634M | $704M | $755M | $798M | $844M |